Does tesamorelin burn fat?
It cut deep belly fat in the group it was approved for. In people with HIV-associated lipodystrophy (abnormal fat buildup), 412 people at 26 weeks saw deep belly fat fall 15.2%, while it rose 5.0% on a dummy shot. Across both large final-stage studies, 806 people pooled, the drug cut deep belly fat by 15.4% more than the dummy shot, with no change in the fat just under the skin. A 61-person study in people with HIV and fatty liver found liver fat fell 4.1 percent more on tesamorelin than on the dummy shot. Those are belly-fat and liver-fat results in people with HIV. They are not a general fat-burning result in people without that diagnosis, and they say nothing about fat under the skin. A research-chemical vial labeled tesamorelin is not Egrifta. This FAQ does not move those VAT numbers onto a general weight-loss claim. Full record at /compounds/tesamorelin.
Studies in people from the compound pages this answer belongs to
- Tesamorelin
- Metabolic effects of a growth hormone-releasing factor in patients with HIV 2007 PMID 18057338
- Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data 2010 PMID 20554713
- Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial 2012 PMID 22869065
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of growth hormone secretagogues. Sermorelin, tesamorelin, ipamorelin, CJC-1295, and the rest of the GHRH and ghrelin receptor family.